Abstract
Recent reports have described the successful treatment of Encephalitozoon intestinalis infection in AIDS patients with albendazole. However, this compound is rapidly metabolized in vivo to albendazole sulfoxide, and furthermore it is only 1 of about 15 commercially developed benzimidazole derivatives. To compare the activities of albendazole, albendazole sulfoxide, and other benzimidazoles, an in vitro system involving infection of green monkey kidney cell (E6) monolayers with E. intestinalis spores was developed. After 14 days, the effects of benzimidazoles on spore production were determined. Ten of fourteen derivatives tested, including albendazole, were inhibitory at concentrations of 1 to 10 ng/ml. Derivatives modified at the 1 or 2 position were less active. Albendazole sulfoxide was 1.7-fold more inhibitory than albendazole but significantly less toxic to E6 cells, a finding that explains the clinical efficacy of this compound. Potential alternatives to albendazole are discussed. No albendazole-resistant E. intestinalis mutants were obtained following in vitro selection.
References
Apr 1, 1992·Antimicrobial Agents and Chemotherapy·M S BartlettJ W Smith
Mar 1, 1992·AIDS·C BlanshardB G Gazzard
Nov 1, 1988·International Journal for Parasitology·E Lacey
Mar 1, 1987·Nature·C R VossbrinckC R Woese
Jan 1, 1982·Advances in Pharmacology and Chemotherapy·H Van den BosscheC Hörig
Jun 1, 1995·Antimicrobial Agents and Chemotherapy·F F FranssenF van Knapen
Sep 1, 1995·The Journal of Eukaryotic Microbiology·M D BakerJ A Shadduck
May 1, 1995·The Journal of Infectious Diseases·M A De GrooteR Reves
Apr 1, 1995·Journal of Clinical Microbiology·G S VisvesvaraI Tyrrell
Jan 1, 1995·The Journal of Infectious Diseases·J M MolinaJ Modaï
Sep 1, 1994·Antimicrobial Agents and Chemotherapy·S K KatiyarT D Edlind
Oct 1, 1994·Clinical Microbiology Reviews·R WeberR L Owen
Oct 1, 1994·Antimicrobial Agents and Chemotherapy·B BeauvaisF Derouin
May 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·D M AsmuthC A Wanke
Sep 1, 1994·Parasitology·T van GoolJ Dankert
Aug 1, 1994·Antimicrobial Agents and Chemotherapy·M S BartlettJ W Smith
Aug 1, 1994·AIDS·E J AaronsB G Gazzard
Aug 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R WeberR Lüthy
Feb 1, 1994·Antimicrobial Agents and Chemotherapy·M C CruzT D Edlind
Jan 1, 1994·The Journal of Infectious Diseases·D T DieterichJ M Orenstein
Jan 1, 1996·The Journal of Eukaryotic Microbiology·E S DidierL M Beaudet
Apr 29, 1996·FEBS Letters·J LiT D Edlind
Jun 1, 1996·Molecular and Biochemical Parasitology·J LiT D Edlind
Feb 1, 1996·Journal of Molecular Evolution·T KamaishiM Hasegawa
Dec 1, 1996·Molecular Biology and Evolution·P J Keeling, W F Doolittle
Citations
Jan 10, 2009·PLoS Pathogens·Donna E AkiyoshiSaul Tzipori
Oct 20, 2018·Expert Opinion on Therapeutic Targets·Bing Han, Louis M Weiss
May 27, 2005·Antimicrobial Agents and Chemotherapy·Jean MenottiJean-Michel Molina
Mar 5, 2008·The Journal of Parasitology·Shajahan JohnyDouglas W Whitman
May 20, 2011·Journal of Clinical Microbiology·Oleg DitrichMartin Kvác
May 1, 2008·Expert Opinion on Drug Discovery·Bj FennellA Bell
Aug 12, 2014·The Journal of Eukaryotic Microbiology·Marianita SantianaAnn Cali
Mar 11, 2020·Antimicrobial Agents and Chemotherapy·Bohumil SakMartin Kváč
Oct 14, 2008·Parasitology Research·Shajahan JohnyDouglas W Whitman
Feb 7, 2015·PloS One·Sebastian Gisder, Elke Genersch
Feb 16, 2007·The Journal of Eukaryotic Microbiology·Donna E AkiyoshiSaul Tzipori
Apr 25, 2013·Antimicrobial Agents and Chemotherapy·Maria Anete LalloJoão Manoel de Castro
Dec 3, 1998·Antimicrobial Agents and Chemotherapy·O Ridoux, M Drancourt
May 4, 2001·The Veterinary Record·C SuterP Deplazes
Oct 27, 2004·Molecular and Biochemical Parasitology·Louisa M MacDonaldJames A Reynoldson
Jul 5, 2021·The Korean Journal of Parasitology·Jong-Yil ChaiSung-Jong Hong
Jul 1, 2021·Clinical Microbiology Reviews·Bing HanLouis M Weiss